Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Abstract: A system to reduce probability of a crash in an intersection is disclosed which includes one or more way-sensor systems, the one or more sensor systems adapted to provide position and velocity vector of an object approaching the intersection on an associated path, a processing unit including configured to: determine timing of the object with respect to a predefined zone of the intersection on the associated path, determine the current and future status of the associated traffic lights on the associated path of the object, predict timing of the object with respect to the predefined zone and future status of the associated traffic light, if timing prediction is within a predetermined threshold, modify the current status, wherein tgreen is extended, if timing prediction is outside of the predetermined threshold, modify the current status, wherein tgreen is reduced, and repeating above steps until the object has cleared the intersection.

Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Abstract: The present disclosure is directed towards systems and methods for assisting with legal research and for aiding in the discovery of information and documents relevant to a user's research focus or input text. The inventive systems receive identifications of relevant documents explicitly or implicitly from a user's research session or input text and, based on issues relevant to those documents, texts and other connections to those documents and texts, recommends similar or helpful documents to the user for their consideration. Recommendations may be ranked and filtered.

Abstract: Methods, systems, and devices for wearing detection are described. A user device may determine a condition to trigger an oxygen saturation measurement, or a measure of blood oxygen saturation (SpO2), for a user of a wearable device. The condition may be based on a physical state of the wearable device, a physiological state of the user, or both. In some examples, the user device may determine the condition based on one or more relationships between sensor data from the wearable device, application data, physiological data from the wearable device, or any combination thereof. The user device may receive a measure of oxygen saturation of the user from the wearable device. The user device may cause a graphical user interface (GUI) of the user device to display an indication of the measure of the oxygen saturation for the user.

Abstract: A datacenter power management system and method is disclosed. A plurality of computing units are enabled to operate at a second frequency, higher than a first frequency, in response to determining from respective power coefficients for these computing units, that a power level at this higher frequency remains below a power budget.

Abstract: In a wavelength selective switch, an input port transmits an input beam, and diffraction grating disperses the input beam into optical channels. A liquid-crystal-on-silicon (LCoS) switch assembly has a phase grating profile and has addressable pixels, which are liquid crystal based. The LCoS switch assembly can selectively direct first-order diffracted beams of the optical channels for output to selected output ports. A tunable optical wedge adjacent the LCoS switch assembly can direct higher-order diffraction beams in the space between the output ports to reduce crosstalk. The wedge is a liquid crystal cell having spaced-apart resistive layers and having liquid crystal material disposed between the layers. In the wedge, the liquid crystal material can produce a phase profile in response to bias voltages applied to the resistive layers, and a beam steering angle of the phase profile can direct at least the second-order diffracted beams towards the port spacing between the ports.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Abstract: A datacenter power management system and method is disclosed.

Abstract: A two-step optimization process is utilized to define an optimal phase profile for a LCoS spatial light modulator. The two-step optimization process first utilizes a nonlinear constrained optimization (NCO) program to determine the specific parameters required to obtain an optimal phase profile (hologram), where the “optimal phase profile” is typically defined as that profile which achieves maximum diffraction efficiency for optical switching. Following this first step, phase scaling (and perhaps an adjustment in the number of pixels per period) is employed to slightly modify the values of the optimal phase profile to effectively suppress crosstalk peaks. If any orders still exhibit an unacceptable level of crosstalk, these orders are then subtracted from the phase profile to create the final design.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Abstract: A two-step optimization process is utilized to define an optimal phase profile for a LCoS spatial light modulator. The two-step optimization process first utilizes a nonlinear constrained optimization (NCO) program to determine the specific parameters required to obtain an optimal phase profile (hologram), where the “optimal phase profile” is typically defined as that profile which achieves maximum diffraction efficiency for optical switching. Following this first step, phase scaling (and perhaps an adjustment in the number of pixels per period) is employed to slightly modify the values of the optimal phase profile to effectively suppress crosstalk peaks. If any orders still exhibit an unacceptable level of crosstalk, these orders are then subtracted from the phase profile to create the final design.

Abstract: A multiple wavelength selective switch has an optics assembly to receive a first input optical signal from a first ingress port and a second input optical signal from a second ingress port. A switch assembly has a single switching mechanism to direct the first input optical signal to the optics assembly as a first output optical signal and the second input optical signal to the optics assembly as a second output optical signal. The switch assembly directs the first output optical signal to a first egress port selected from the first set of egress ports and directs the second output optical signal to a second egress port selected from the second set egress ports. The first egress port and the second egress port have the same wavelength channel. The multiple wavelength selective switch supports an arbitrary number of wavelength channels that can be switched at the same time. Each switch assembly directs signals from a set of ingress ports to a set of egress ports sharing the same wavelength channel.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: A dual-band input transceiver block is formed to operably receive one of a 2.4 GHz radio frequency signal or a 5.0 GHz radio frequency transceiver signal in a manner that minimizes duplication of circuitry and creates a combined circuit path for RF front end input stages for much of the input stage. More specifically, the embodiments of the present invention include separate amplification and mixing stages whose outputs are combined by a stabilized load with circuitry for removing a common mode feedback signal. As such, downstream components, such as amplifiers, filters, analog-to-digital converters, and other input path circuit elements, are not duplicated and may be used regardless of whether the dual-band transceiver is operating in a first or second frequency band. Operation is, in the described embodiment, only one frequency input at a time though the invention is not limited to such operation.